info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Risdiplam Tablets (Evrysdi)
501
Article source: Seagull Pharmacy
Oct 22, 2025

Risdiplam Tablets (Evrysdi) is an SMN2 splicing modifier used for the treatment of adult and pediatric patients with spinal muscular atrophy (SMA). As a breakthrough drug in the field of gene therapy, its use must strictly follow the age- and weight-based graded dosing regimen.

Indications for Risdiplam Tablets (Evrysdi)

Core Treatment Scope

Risdiplam is indicated for the treatment of genetically confirmed spinal muscular atrophy.

Pre-symptomatic SMA: Infants who have not yet developed clinical symptoms (first dose administered at ≤ 6 weeks of age).

Infantile SMA (Type 1): Symptoms appear between 28 days and 3 months of age.

Late-onset SMA (Type 2 or 3): Symptoms appear after 18 months of age.

Usage Restrictions

Dosing regimen: Must be administered strictly according to age and weight stratification.

Contraindications: No absolute contraindications are listed in the current package insert.

Special monitoring: Regular assessment of motor function milestone progression is required.

Specifications and Properties of Risdiplam Tablets (Evrysdi)

Basic Parameters

Dosage form: Oral solution (requires reconstitution) and film-coated tablets.

Tablet strength: 5mg per tablet (pale yellow, round, biconvex tablets, engraved with "EVR" on one side).

Oral solution strength: 60mg per vial (after reconstitution, it becomes a yellow-green solution with a concentration of 0.75mg/mL).

Formulation Components

Active ingredient: Risdiplam.

Tablet excipients: Colloidal silicon dioxide, crospovidone, mannitol, etc.

Solution excipients: Ascorbic acid, disodium edetate, isomalt, etc.

Dosage Form Characteristics

Tablets: Can be swallowed whole or dissolved in non-chlorinated drinking water (e.g., filtered water).

Oral solution: Must be administered using a dedicated oral syringe and must not be mixed with formula milk/milk.

Storage Methods for Risdiplam Tablets (Evrysdi)

Unreconstituted Powder

Temperature: Store at room temperature (15-30℃) in accordance with USP room temperature control regulations.

Light protection requirement: Keep in the original packaging.

Expiration date: Refer to the label on the vial.

Reconstituted Solution

Refrigerated storage: Store upright at 2-8℃ (must be used within 64 days).

Room temperature stability: Can be stored at a temperature not exceeding 40℃ for a total of 5 days.

Light protection requirement: Must be kept in the original amber vial.

Tablet Storage

Routine conditions: Store at 20-25℃ (short-term fluctuations between 15-30℃ are allowed).

Moisture-proof measure: Keep the bottle cap tightly closed.

Dispersion: Prepare and use immediately (administer within 10 minutes).

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
What Are the Side Effects of Alemtuzumab Injection (Lemtrada)?
Alemtuzumab Injection (Lemtrada) is a CD52-directed cytolytic monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Despite its significant efficacy, this medication may cau...
How to Use Lomitapide (Juxtapid)
Lomitapide (Juxtapid) is a microsomal triglyceride transfer protein (MTP) inhibitor, used for the treatment of homozygous familial hypercholesterolemia (HoFH).How to Use Lomitapide (Juxtapid)Standard ...
Indications for Lomitapide (Juxtapid)
Lomitapide (Juxtapid) is a medication used to treat specific lipid metabolism disorders, with lomitapide as its active ingredient.Indications for Lomitapide (Juxtapid)Primary Therapeutic UsesLomitapid...
How to Purchase Lomitapide Capsules (Juxtapid)
Lomitapide Capsules (Juxtapid) are an oral microsomal triglyceride transfer protein (MTP) inhibitor indicated for the treatment of homozygous familial hypercholesterolemia (HoFH). Due to the drug’s sp...
How to Purchase Decitabine and Cedazuridine Combination Tablets (INQOVI)
Decitabine and Cedazuridine Combination Tablets (INQOVI) are a prescription medication used for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Due to its ...
How to Use Decitabine and Cedazuridine Combination Tablets (INQOVI)
Decitabine and Cedazuridine Combination Tablets (INQOVI) are an oral medication used for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Its unique formula...
Precautions for Administration of Decitabine and Cedazuridine Tablets (INQOVI)
Decitabine and Cedazuridine Tablets (INQOVI) is an oral targeted drug used for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).Precautions for Administratio...
What Are the Side Effects of Decitabine and Cedazuridine Tablets (INQOVI)?
Decitabine and Cedazuridine Tablets (INQOVI) is an oral medication used for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). As an innovative therapy, its e...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved